Clinical Trial Update: Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Acral Melanoma | Phase 3 | Status: RECRUITING